A double-blind trial: vivalan against placebo in depressed elderly patients

Abstract

A double-blind controlled study of viloxazine against placebo in elderly depressed patients with a primary diagnosis of depressive illness records statistically significant improvements in depression ratings in the viloxazine group after three weeks. Viloxazine was effective and well tolerated at doses of 100 to 200 mg in depressed elderly patients, several of whom had concurrent cardiac disease.